Flt-3 and c-kit mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell disease

被引：35

作者：

Pardanani, A

Reeder, TL

Kimlinger, TK

Baek, JY

Li, CY

Butterfield, JH

Tefferi, A

机构：

[1] Mayo Clin, Div Hematol & Internal Med, Rochester, MN 55905 USA

[2] Mayo Clin, Div Hematopathol, Rochester, MN 55905 USA

[3] Mayo Clin, Div Allerg Dis & Internal Med, Rochester, MN 55905 USA

来源：

LEUKEMIA RESEARCH | 2003年 / 27卷 / 08期

关键词：

leukemia; receptor tyrosine kinase; stem cells; hematologic clonal malignancies; c-kit mutation;

D O I：

10.1016/S0145-2126(02)00303-X

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We screened 115 patients with chronic myeloid disorders (CMD) for known flt-3 and c-kit mutations in both the juxtamembrane (M) and the activation loop (AL) domains. None of the patients displayed flt-3 (JM or AL) or c-kit JM mutations. However, the c-kit AL (D816V) mutation was detected in 5 of 16 patients with systemic mast cell disease (SMCD) but in none of the remaining 99 patients with other CMD. In SMCD, the presence of D816V mutation was significantly associated with advanced age, an aggressive clinical course, increased bone marrow mast cell content, and chronic myelomonocytic leukemia. (C) 2003 Elsevier Science Ltd. All rights reserved.

引用

页码：739 / 742

页数：4